Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
Fiche publication
Date publication
décembre 2019
Journal
BMC cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr FAIVRE Jean-Christophe
Tous les auteurs :
Kissel M, Martel-Lafay I, Lequesne J, Faivre JC, Le Péchoux C, Stefan D, Barraux V, Loiseau C, Grellard JM, Danhier S, Lerouge D, Chouaid C, Gervais R, Thariat J
Lien Pubmed
Résumé
Stereotactic irradiation (SBRT) is a standard of care for inoperable stage I lung cancer and brain oligometastases from lung cancer but is controversial for extracranial oligometastases. We assessed outcomes of lung cancer patients with extracranial metastases in oligometastatic, oligorecurrent, oligopersistent and oligoprogressive settings ("oligometastatic spectrum") under strategies using SBRT +/- systemic treatments.
Mots clés
Lung cancer, Oligometastasis, Stereotactic radiotherapy, Survival, Systemic treatment
Référence
BMC Cancer. 2019 Dec 19;19(1):1237